In addition, since VX-770 is also used for the new FDA-approved pharmacological combination Trikafta® [25], study on the adverse effects of a potentiator on CFTR plasma membrane stability remains a high priority, and could be useful to better address new therapeutic strategies for CF. This evidence concerns the gene CFTR and cystic fibrosis.